Nuclera is a life sciences technology company founded in 2013 by scientists at the University of Cambridge. It builds technology that gives researchers rapid, reliable access to functional proteins, addressing a persistent bottleneck in protein-dependent research: obtaining enough well-behaved protein material to run experiments.
The company's eProtein Discovery platform integrates cell-free protein expression, digital microfluidics, automated multiplex screening, purpose-built cartridges and reagents, and cloud-based software. Researchers use it to design constructs, compare solubility tags and expression conditions, characterise results and scale promising proteins, with assay-ready protein material produced in as little as 48 hours. The workflow replaces repeated rounds of trial and error with scaling and characterisation completed within days.
Engineering work at Nuclera spans several technical domains:
- cell-free protein expression
- digital microfluidics
- automated multiplex screening
- cartridge and reagent development
- cloud-based software
- protein engineering and characterisation
The company is headquartered in Cambridge, UK, and operates a research and cartridge-manufacturing facility in Massachusetts, USA. Its stated mission is to remove uncertainty from protein science, with an emphasis on reliability, speed and reproducibility for research teams.
